Mid-Day Market Update: Benefytt Technologies surges following acquisition news; NextCure shares slide
|Midway through trading Monday, the Dow traded up 1.64% to 26503.64 while the NASDAQ rose 1.92% to 10,821.08. The S&P also rose, gaining 1.42% to 3,230.31.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 3,304,940 cases with around 135,200 deaths. Brazil confirmed a total of over 1,864,680 COVID-19 cases with 72,100 deaths, while India reported a total of at least 878,250 confirmed cases and 23,170 deaths. In total, there were at least 12,910,350 cases of COVID-19 worldwide with over 569,120 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Consumer discretionary shares rose 2.5% on Monday. Meanwhile, top gainers in the sector included Vuzix Corporation VUZI 13.94%, up 15%, and Tesla, Inc. TSLA 13.05%, up 14%.
In trading on Monday, energy shares fell 0.2%.
Top Headline
Pepsico reported quarterly earnings of $1.32 per share, beating analysts’ estimates of $1.25 per share. The company reported sales of $15.95 billion, exceeding expectations of $15.38 billion.
Equities Trading UP
Equillium, Inc. EQ 155.8% shares shot up 156% to $8.17 after the company disclosed that Itolizumab significantly reduced mortality in coronavirus patients, according to a clinical trial conducted in India by its partner Biocon.
Shares of electroCore, Inc. ECOR 183.53% got a boost, shooting 175% to $2.3399 after the company announced it has received FDA emergency use authorization for the use of gammaCore Sapphire CV for acute treatment of asthma exacerbations in COVID-19 patients.
Benefytt Technologies, Inc. BFYT 37.68% shares were also up, gaining 38% to $30.77 after the company agreed to be acquired by Madison Dearborn Partners for $31 per share.
Equities Trading DOWN
Celsion Corporation CLSN 61.59% shares tumbled 63% to $1.31 after the company received a recommendation from its independent data monitoring committee to consider stopping its Phase 3 OPTIMA study due to efficacy concerns.
Shares of NextCure, Inc. NXTC 44.98% were down 46% to $9.69 after the company said it would not advance its non-small cell lung cancer and ovarian cancer studies. The company's chief medical officer also departed the company. SunTrust Robinson Humphrey downgraded NextCure from Buy to Hold and lowered the price target from $78 to $13.
Gritstone Oncology, Inc. GRTS 50.99% was down, falling 47% to $4.25 after the company gave an update on its immunotherapy product candidates.
Commodities
In commodity news, oil traded down 0.1% to $40.53, while gold traded up 0.4% to $1,809.40.
Silver traded up 3.1% Monday to $19.635, while copper rose 2.3% to $2.9645.
Euro zone
European shares were higher today. The eurozone’s STOXX 600 rose 0.83%, the Spanish Ibex Index rose 1.32%, while Italy’s FTSE MIB Index gained 0.95%. Meanwhile, the German DAX 30 gained 1.08%, French CAC 40 gained 1.41% and UK shares rose 1.3%.
Economics
Federal Reserve Bank of Dallas President Robert Kaplan will speak at 1:00 p.m. ET.
The U.S. Treasury budget report for June is scheduled for release at 2:00 p.m. ET.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.